Lilly’s Foundayo 17.2 mg beats oral semaglutide 25 mg on weight loss

Data ReadoutpositiveFoundayoSemaglutidePositive

AI Analysis

Summary

Lilly's Foundayo 17.2 mg demonstrated superior weight loss efficacy compared to oral semaglutide 25 mg in a clinical comparison, positioning the drug favorably in the competitive weight loss market.

Clinical Trial Data

Primary Endpoint

Met

Outcome Details

Foundayo 17.2 mg demonstrated superior weight loss efficacy compared to oral semaglutide 25 mg

Importance:7/10

Sentiment:

0.80

weight lossobesityclinical trialcompetitive comparisonGLP-1

Related Companies

$LLY

Read the original article

Published by Seeking Alpha Healthcare on September 29, 2026 7:14 AM

Read Original